Container closures
Product Description
Siegfried AG
-
CH
-
2015On CPHI since
-
3Certificates
-
1000 - 4999Employees
Company types
Siegfried AG
-
CH
-
2015On CPHI since
-
3Certificates
-
1000 - 4999Employees
Company types
More Products from Siegfried AG (25)
-
Product Amlodipine mesylate
Siegfried Ltd. offers wide range of products and services which includes amlodipine mesylate. Therapeutic areas: hypertension. Contact us for more information. -
Product Aseptic filling
Siegfried Ltd. offers wide range of products and services which includes aseptic filling. It includes suspensions, gels, ointments, etc. Contact us for more information. -
Product Candesartan
Siegfried Ltd. offers wide range of products and services which includes candesartan. Therapeutic areas: hypertension. Contact us for more information. -
Product Clinical trial production
Siegfried Ltd. offers wide range of products and services which includes clinical trial production. Contact us for more information. -
Product Cmc documentation services
Siegfried Ltd. offers wide range of products and services which includes cmc documentation services. Contact us for more information. -
Product Combination/drug delivery devices
Siegfried Ltd. offers wide range of products and services which includes combination/drug delivery devices. It includes drug coating implants, drug delivery services, sustained release delivery system. Contact us for more information. -
Product Design for manufacture & scale up
Siegfried Ltd. offers wide range of products and services which includes design for manufacture & scale up. Contact us for more information. -
Product Doxazosin
Siegfried Ltd. offers wide range of products and services which includes doxazosin. Therapeutic areas: hypertension. Contact us for more information. -
Product Felodipine
Siegfried Ltd. offers wide range of products and services which includes felodipine. Therapeutic areas: hypertension. Contact us for more information. -
Product Final formulation
Siegfried Ltd. offers wide range of products and services which includes final formulation. Contact us for more information. -
Product Finasteride
Siegfried Ltd. offers wide range of products and services which includes finasteride. Therapeutic areas: benign prostate hyperplasia. Contact us for more information. -
Product Fluoxetine
Siegfried Ltd. offers wide range of products and services which includes fluoxetine. Therapeutic areas: depression. Contact us for more information.
Siegfried AG resources (9)
-
News On track at CPHI Barcelona - The Track Sponsor interviews: Siegfried
In our packed out content sessions at CPHI Barcelona this year we focus on some of the hottest topics coming up in the pharma industry, with each track sponsored by a leading expert in the field. -
Webinar From Lab to Commercial Production -How to Combat Challenges in OSD High Potency Products Development
Highly Potent APIs are a rapidly growing segment of the global pharmaceutical industry, and they are acquiring a significant relevance into the development space. The importance to understand the challenges around development of High Potency Oral solids formulations, are the key to ensure a right scale-up and launch Risk-based approach: measuring the risk, not the hazard Challenges for High potency products handling. Importance of select the adequate partner Development of secure and scalable process in high containment environment -
News Siegfried starts to ramp up production after cyber attack
Hameln plant which provides fill and finish for Pfizer-BioNTech COVID-19 shot should be fully operational within the week, CDMO says -
Webinar Building a Collaborative Supply Chain for Biological Products: A Roadmap for the Future
The Covid-19 Pandemic forced us to learn new ways of collaborating and innovating to solve a global crisis - what can we learn and leverage from this experience as we adapt to a 'new normal'?
Amazing scientific development and break-throughs are evolving faster than ever, with new advanced treatment options for patients being developed at unprecedented speed. All of us involved in manufacturing and supply need to rethink how we collaborate, deliver medicines and learn faster.
No one company can solve this alone - requiring us to collaborate, innovate and learn in new ways. What does this change really mean for us? Welcome to engage in a discussion, sharing case study data and recent insights in the middle of an industry learning journey. -
Webinar Process Optimization for Viral Vector Manufacturing
Though viral vectors are used extensively in cell and gene therapy, the challenges of manufacturing such complex biologics at industrial scale is still a limitation to its broader use.
Dr. Ayuso will speak about how upstream and downstream process optimization using design of experiments (DOE), a platform approach and end-to-end capabilities can tackle manufacturing challenges and help to expedite drug development. -
Webinar Keynote Address: Next-Gen Biomanufacturing
Join Asklepios BioPharmaceutical's former CEO Shelia Ann Mikhail, where she will Set the Scene for the latest innovations and developments affecting the Biomanufacturing Landscape -
Webinar Overcoming Challenges in Transferring a Sterile Biologics Drug Product to a CDMO
Ensuring quality and compliance in bio-manufacturing Closing gaps in development data prior to the first GMP production Adjusting manufacturing processes throughout the course of a site-to-site transfer Fulfilling special requirements on container closure systems for biologics Transferring analytical methods for drug products and drug substances -
Webinar Building a Collaborative Supply Chain for Biological Products: A Roadmap for the Future
The Covid-19 Pandemic forced us to learn new ways of collaborating and innovating to solve a global crisis - what can we learn and leverage from this experience as we adapt to a new normal? Amazing scientific development and break-throughs are evolving faster than ever, with new advanced treatment options for patients being developed at unprecedented speed. All of us involved in manufacturing and supply need to rethink how we collaborate, deliver medicines and learn faster.
No one company can solve this alone - requiring us to collaborate, innovate and learn in new ways. What does this change really mean for us? Welcome to engage in a discussion, sharing case study data and recent insights in the middle of an industry learning journey. -
Webinar "Panel: Strategies for Commercialising Cell and Gene Therapies"
Manufacturers face unique quality challenges that can hinder progress. In this session, discover quality challenges in Cell and Gene Therapy (CGT) and learn common practices for overcoming them:
Where are all the approvals? Understanding unique manufacturing challenges for Autologous Cell Therapies How does development by design, quality by design, and Cell Therapy COGs converge in this new space? Creating a Cell Therapy technology roadmap to address challenges and drive speed-to-market
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance